Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manabu Morimoto

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world settingTaito Fukushima, Manabu Morimoto, Makoto Ueno, et al.
The Oncologist|April 6, 2023
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabTaito Fukushima, Manabu Morimoto, Satoshi Kobayashi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 4, 2024
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
European Journal of Gastroenterology & Hepatology|July 3, 2023
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapyHaruki Uojima, Makoto Chuma, Hisashi Hidaka, et al.
BMC Cancer|May 7, 2022
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[A Case of Primary Liposarcoma Arising from the Duodenum]Keisuke Kazama, Toru Aoyama, Masaaki Murakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[A Case of Primary Splenic Inflammatory Myofibroblastic Tumor]Yosuke Atsumi, Masaaki Murakawa, Koichiro Yamaoku, et al.
Journal of Gastroenterology|February 29, 2020
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trialMasatoshi Kudo, Takuji Okusaka, Kenta Motomura, et al.
Scientific Reports|November 24, 2015
Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in JapaneseMakoto Ueno, Shinichi Ohkawa, Manabu Morimoto, et al.
Cancer Science|July 28, 2020
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinomaMasatoshi Kudo, Manabu Morimoto, Michihisa Moriguchi, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world settingTaito Fukushima, Manabu Morimoto, Makoto Ueno, et al.
The Oncologist|April 6, 2023
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabTaito Fukushima, Manabu Morimoto, Satoshi Kobayashi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 4, 2024
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
European Journal of Gastroenterology & Hepatology|July 3, 2023
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapyHaruki Uojima, Makoto Chuma, Hisashi Hidaka, et al.
BMC Cancer|May 7, 2022
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[A Case of Primary Liposarcoma Arising from the Duodenum]Keisuke Kazama, Toru Aoyama, Masaaki Murakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[A Case of Primary Splenic Inflammatory Myofibroblastic Tumor]Yosuke Atsumi, Masaaki Murakawa, Koichiro Yamaoku, et al.
Journal of Gastroenterology|February 29, 2020
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trialMasatoshi Kudo, Takuji Okusaka, Kenta Motomura, et al.
Scientific Reports|November 24, 2015
Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in JapaneseMakoto Ueno, Shinichi Ohkawa, Manabu Morimoto, et al.
Cancer Science|July 28, 2020
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinomaMasatoshi Kudo, Manabu Morimoto, Michihisa Moriguchi, et al.
Pageof 16